Table 1: Demographic and clinical characteristics of the study population, according to development of CIN.

Malen(%)

182(77.1%)

41(64.1%)

0.010

Age (years)

63.1±11.2

64.8±9.5

0.141

BMI,(Kg/m2

24.2±2.9

24.4±3.3

0.333

Hypertensionn(%)

122(51.7%)

33(51.6%)

0.110

Diabetesn (%)

29(12.3%)

15(23.4%)

0.010

Stroken (%)

21(8.90%)

7(10.9%)

0.160

Emergent interventionn (%)

52(22.0%)

22(34.4%)

0.020

Heart failuren (%)

154(65.3%)

49(76.6%)

0.030

Multivessel lesionn (%)

183(77.5%)

55(85.9%)

0.050

Hematocritn (%)

41.0±6.5

40.2±6.6

0.194

Contrast agent dose, (ml)

126.8±61.9

131.3±60.6

0.305

Rehydration therapyn (%)

185(78.4%)

43(67.2%)

0.020

Albumin(g/L)

40.3±3.8

38.9±4.9

0.009

BUN(mmol/L)

5.98±2.69

6.04±2.90

0.441

Serum creatinine(μmol/L)

87.5±49.4

92.4±28.3

0.154

Uric acid(μmol/L)

362.2±99.83

382.3±137.4

0.137

Cystatin(mg/L)

0.99±0.39

1.01±0.40

0.345

AST(U/L)

36.6 (21.5-146.9)

78 (23.9-212.0)

0.324

TBIL(μmol/L)

10.3±5.89

11.4±7.36

0.104

Potassium(mmol/L)

3.88±0.53

3.95±0.62

0.186

Calcium;,(mmol/L)

2.21±0.20

2.18±0.18

0.241

Phosphorus(mmol/L)

1.06±0.34

1.08±0.32

0.386

Glucose(mmol/L)

7.82±4.80

9.29±6.76

0.025

CHOL(mmol/L)

5.38±1.28

5.44±1.51

0.383

Triglyceride(mmol/L)

1.95±1.48

1.73±1.04

0.140

LDL-C(mmol/L)

3.26±1.02

3.20±1.07

0.331

NT-proBNP(pg/ml)

176 (70.6-504)

275 (85.7-580)

0.017

eGFR(simplified MDRD formula)(ml/min/1.73m²)

89.8±33.9

79.0±24.5

0.002

CIN:contrast-induced nephropathy; BMI:body mass index;BUN:Blood urea nitrogen; AST:aspartate aminotransferase;TBIL:total bilirubin;CHOL:total cholesterol; LDL-C:low density lipoprotein cholesterin; NT-proBNP:N-terminal pro brain natriuretic peptide; eGFR:glomerular filtration rate; simplified MDRD formula:eGFR=186×(Scr)-1.154×(Age)-0.203×(0.742 If Female).